Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.

Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas

This study investigates the efficacy and safety of sonic hedgehog inhibitors (SHHis) in treating basal cell carcinomas (BCCs), a common type of skin cancer. The authors conducted a systematic review and meta-analysis of existing research, comparing the efficacy and safety of different SHHi molecules. Their findings reveal that SHHis, while offering an additional treatment option for BCC, particularly in metastatic or locally advanced cases, can induce a partial response to the disease.

Comparison of SHHi Molecules

The study found that vismodegib and sonidegib, two commonly used SHHi molecules, have similar overall response rates in locally advanced BCC. However, sonidegib is associated with a higher prevalence of upper gastrointestinal distress compared to vismodegib. In metastatic BCC, vismodegib demonstrated a significantly higher overall response rate than sonidegib.

Side Effects and Considerations

It's important to note that SHHis are associated with common side effects, including muscle spasms, dysgeusia (altered taste), and alopecia (hair loss). These side effects are often similar across different SHHi molecules and can lead to high discontinuation rates.

Dr. Camel's Conclusion

This research provides valuable insights into the efficacy and safety of SHHis in the treatment of BCC. Just as the desert landscape can shift and change over time, our understanding of cancer treatments is also constantly evolving. This study serves as a reminder that effective treatments often come with a cost, and it's important to weigh the potential benefits against the risks. It also underscores the importance of careful patient selection and individualized treatment plans to optimize outcomes and manage potential side effects.